Bannwarth Sylvie, Procaccio Vincent, Paquis-Flucklinger Veronique
Department of Medical Genetics, Hopital Archet 2, CHU Nice, France.
Hum Mutat. 2005 Jun;25(6):575-82. doi: 10.1002/humu.20177.
Molecular analysis of mitochondrial DNA (mtDNA) is a critical step in diagnosis and genetic counseling of respiratory chain defects. No fast method is currently available for the identification of unknown mtDNA point mutations. We have developed a new strategy based on complete mtDNA PCR amplification followed by digestion with a mismatch-specific DNA endonuclease, Surveyor Nuclease. This enzyme, a member of the CEL nuclease family of plant DNA endonucleases, cleaves double-strand DNA at any mismatch site including base substitutions and small insertions/deletions. After digestion, cleavage products are separated and analyzed by agarose gel electrophoresis. The size of the digestion products indicates the location of the mutation, which is then confirmed and characterized by sequencing. Although this method allows the analysis of 2 kb mtDNA amplicons and the detection of multiple mutations within the same fragment, it does not lead to the identification of homoplasmic base substitutions. Homoplasmic pathogenic mutations have been described. Nevertheless, most homoplasmic base substitutions are neutral polymorphisms while deleterious mutations are typically heteroplasmic. Here, we report that this method can be used to detect mtDNA mutations such as m.3243A>G tRNA(Leu) and m.14709T>C tRNA(Glu) even when they are present at levels as low as 3% in DNA samples derived from patients with respiratory chain defects. Then, we tested five patients suffering from a mitochondrial respiratory chain defect and we identified a variant (m.16189T>C) in two of them, which was previously associated with susceptibility to diabetes and cardiomyopathy. In conclusion, this method can be effectively used to rapidly and completely screen the entire human mitochondrial genome for heteroplasmic mutations and in this context represents an important advance for the diagnosis of mitochondrial diseases.
线粒体DNA(mtDNA)的分子分析是呼吸链缺陷诊断和遗传咨询中的关键步骤。目前尚无快速方法可用于鉴定未知的mtDNA点突变。我们开发了一种新策略,即先进行完整的mtDNA PCR扩增,然后用错配特异性DNA内切酶Surveyor Nuclease进行消化。这种酶是植物DNA内切酶CEL核酸酶家族的成员,可在任何错配位点切割双链DNA,包括碱基替换和小的插入/缺失。消化后,通过琼脂糖凝胶电泳分离并分析切割产物。消化产物的大小表明突变的位置,然后通过测序进行确认和表征。尽管该方法可分析2 kb的mtDNA扩增子并检测同一片段内的多个突变,但它无法鉴定同质性碱基替换。已有同质性致病突变的报道。然而,大多数同质性碱基替换是中性多态性,而有害突变通常是异质性的。在此,我们报告该方法可用于检测mtDNA突变,如呼吸链缺陷患者DNA样本中低至3%水平存在的m.3243A>G tRNA(Leu)和m.14709T>C tRNA(Glu)。然后,我们对五名患有线粒体呼吸链缺陷的患者进行了检测,在其中两名患者中鉴定出一种变异(m.16189T>C),该变异先前与糖尿病和心肌病易感性相关。总之,该方法可有效地用于快速、全面地筛查整个人类线粒体基因组中的异质性突变,在此背景下代表了线粒体疾病诊断的一项重要进展。